Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eupraxia PharmaceuticalsTSX:EPRX +2.92%34 Net Debt Paydown Yield % is 0.14% as of Jul. 16, 2026, which is 92% below its 10-year median of 1.72. GuruFocus rates TSX:EPRX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,163 Biotechnology companies, Eupraxia Pharmaceuticals ranks better than 58.64% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Eupraxia Pharmaceuticals's Net Debt Paydown Yield % was 0.14%.
Eupraxia Pharmaceuticals (TSX:EPRX) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Eupraxia Pharmaceuticals Net Debt Paydown Yield % Related Terms
Eupraxia Pharmaceuticals Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Eupraxia Pharmaceuticals's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eupraxia Pharmaceuticals Net Debt Paydown Yield % Chart
TSX:EPRX vs VRTX, REGN, ALNY: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Eupraxia Pharmaceuticals's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eupraxia Pharmaceuticals Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Eupraxia Pharmaceuticals's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.14% mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a Net Debt Paydown Yield % of 0.14% as of Jul. 16, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Eupraxia Pharmaceuticals and its competitors. This is 92% below median its historical median of 1.72. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #481 out of 1163 companies in the Biotechnology industry, placing it in the top 41.4%.
Is Eupraxia Pharmaceuticals' Net Debt Paydown Yield % too high?
Eupraxia Pharmaceuticals' current Net Debt Paydown Yield % of 0.14% is 92% below median its 10-year median of 1.72. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Eupraxia Pharmaceuticals' value of 0.14% is 366.7% above this industry median. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #481 out of 1163 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #481 out of 1163 companies for Net Debt Paydown Yield %. This puts Eupraxia Pharmaceuticals in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.03. Eupraxia Pharmaceuticals' value of 0.14% is 366.7% above this benchmark. While the company's 10-year median is 1.72 vs. the industry median of 0.03, Eupraxia Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,163 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eupraxia Pharmaceuticals's current Net Debt Paydown Yield % of 0.14% is 366.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Eupraxia Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eupraxia Pharmaceuticals's current Net Debt Paydown Yield % is 0.14%, which is 92% below median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current Net Debt Paydown Yield % of 0.14%. The current Net Debt Paydown Yield % is 0.14%, which is 92% below median its 10-year median of 1.72 and 366.7% above the Biotechnology industry median of 0.03. Eupraxia Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current Net Debt Paydown Yield % is 0.14% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
34GF Score
Get the complete analysis for TSX:EPRX
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:EPRX has been successfully added to your 
